Phase II study of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Summary
The purpose of this phase II study is to evaluate the safety and efficacy of Capecitabine and Temozolomide after surgery in patients with high-risk well- differentiated pancreatic neuroendocrine tumors.
General Information
NCT#: NCT05040360
Study ID: S2104
Trial Phase: Phase II
Trial Sponsor: Southwest Oncology Group (SWOG)
Therapies Used in This Trial: Capecitabine, Temozolomide